PRLD
NASDAQ · Healthcare · Biotechnology · US
Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$0.16
- Revenue estimate
- $35.3M
Latest reported
- Last report date
- Aug 11, 2026
- EPS actual
- -$0.14
- EPS estimate
- -$0.20
- Revenue actual
- $5.7M
- Revenue estimate
- $5.7M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 9
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -115.1%
- Revenue beats (12Q)
- 0
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $8.00
- PT range
- $8.00 – $8.00
- Analysts
- 2
Q4 FY2025 · Mar 10, 2026
AI summary of management’s prepared remarks and analyst Q&A · For informational purposes only, not investment advice
Management highlights
Discussed aspects such as the clinical development plan for molecule 396 including a parallel design in myelofibrosis and polycythemia vera with input from key opinion leaders, the rationale behind choosing a degrader approach for CAT6 including selectivity and efficacy advantages, and work on the mutant Cal-R degrader with differentiation points like potency and potential for subcutaneous administration.
Guidance
Cash position was $106 million in cash, which takes the company into the second quarter of 2027, and this does not account for the potential $100 million option payment from Insight.
Segment performance
Not explicitly mentioned in detail
Risks & headwinds
Not discussed in detail
Analyst Q&A
Q: Can you differentiate your molecule from other competitors and why Insight would partner with you?
A: Discussed selectivity profile, learnings from clinic/preclinical stages, and parallel clinical development plan.
Q: Talk about the clinical development plan for molecule 396?
A: Parallel design in myelofibrosis and polycythemia vera, enrolling the right patients and getting FDA approval for the parallel approach.
Q: Talk about the CAT6 degrader?
A: Differentiated by degrader approach for better selectivity and efficacy, plan to file IND by mid - year.
Q: What is the cash position?
A: $106 million in cash, lasting into the second quarter of 2027
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026